Kazia Therapeutics
@kaziatherapeutics.com
Kazia is an Australian oncology company developing innovative, high-impact drugs for cancer. Our lead program is paxalisib, which is being developed to treat glioblastoma, the most common and most aggressive form of primary brain cancer in adults.
Kazia Therapeutics's Company Logos
Kazia Therapeutics's Brand Colors
Hex Code
Color name
RGB
HSL
CMYK
#4DBEEA
Picton Blue
77, 190, 234
197, 79, 61
67, 19, 0, 8
#50BEE7
Picton Blue
80, 190, 231
196, 76, 61
65, 18, 0, 9
#000000
Black
0, 0, 0
0, 0, 0
0, 0, 0, 100
About Kazia Therapeutics
Kazia Therapeutics is an Australian oncology company that is dedicated to developing pioneering drugs for cancer treatment. Their primary focus is on glioblastoma, which is the most common and aggressive form of primary brain cancer in adults. Their lead program, paxalisib, shows great promise in the treatment of this devastating disease.
Kazia Therapeutics prides itself on a team that possesses extensive expertise in drug development and is committed to providing top-notch service. Their mission is to make a tangible difference in the lives of patients by offering innovative and high-impact therapies. The company collaborates with various partners and researchers to further their advancements in cancer treatment.
They also offer drug access programs for patients participating in clinical trials or compassionate use cases. Investors can find detailed information about the company's financial reports, corporate announcements, and annual reports on their website. Kazia Therapeutics is driven by a genuine passion to revolutionize cancer treatment and improve outcomes for patients worldwide
Company type
Public Company
Year founded
1994
Company size
2-10 employees
Related Brands
Tags
Oncology drug development
Clinical-stage biotechnology
Brain cancer therapeutics
PI3K inhibitor therapies
